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Adrenergic receptors are responsible for selective rec-
ognition and binding of catecholamines and may in turn 
have an effect on epidermal cell growth and maturation 
via adenosine-3',5'-monophosphate (cAMP). Using en-
dogenous catecholamines and drugs specific for a- and 
,8-receptor subtypes, we have characterized the adrener-
gic receptor coupled to adenylate cyclase in cultured 
human epidermal keratinocytes. The relative potency 
order of stimulation of adenylate cyclase was: isoproter-
enol > epinephrine » norepinephrine. The predominant 
adrenergic receptor is of the ,82-subtype, as also con-
firmed by use of the selective antagonists propranolol, 
butoxamine, and atenolol. No evidence of a-adrenergic 
receptor mediation of adenylate cyclase was noted with 
the a2-specific agonist, clonidine. Phenylephrine, the a1-
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Abbreviations: 
cAMP: adenosine-3 ',5'-monophosphate 
E PI: epinephrine 
IBMX: isobutylmethylxanthine 
ISP: isoproterenol 
NE: norepinephrine 
PBS: phosphate-buffered saline 
PRP: propranolol 
RIA: radioimmunoassay 
specific agonist, affected cAMP formation but this r e -
sponse could not be totally inhibited with prazosin, sug-
gesting an unknown mechanism of action. Human k e r-
atinocytes retained the same ,8-adrenergic receptor po-
tency order properties throughout growth and matura-
tion. 
In many mammaljan systems cyclic AMP affects cellular 
metabolism by processes leading to growth enha ncemen t or 
restriction . Epidermal keratinocytes possess a series of cell 
surface receptors for catechola mines [1], histamine [2), adeno-
sine [3,4), and prostaglandins E 1 and E2 [5] which are coupled 
to adenylate cyclase. While species differences do occu1· in the 
magnitude of response a nd order of sensitivity to a variety of 
agonjsts, we previously have shown that the adenylate cyclase 
of human keratinocytes is most sensitive to agents that stimu-
late the catecholamine receptor [6]. That this receptor m ay be 
important with regard to regulation of epidermal growth is 
suggested by the fa ct that several laboratories have indepen-
dently reported that involved psoriat ic epidermis in vitro has a 
decreased response to catecholamines [7- 9], which has been 
confirmed by cytochemical a nalysis [10]. Also, in tissue s lices 
of epidermis t hat had been treated with hexadecane to produce 
hyperplasia, t he increased proliferation, amino acid incorpora-
t ion, and glycolysis were associated with loss of responsiveness 
to ,8-adrenergic agonists [ 11]. 
Adrenergic receptors a re responsible for selective recognjtion 
and binding of catecholamines a nd may mediate qu ite distinct 
cell fun ctions. B eta-adrenergic receptors have been ident ified 
on membra ne preparations of numerous ma mmalia n cells in-
cluding rodent a nd human skin cells [12-14). In this commu-
nication we focus on characterization of the recep tor subtypes 
coupled to adenylate cyclase in human epidermal keratinocyte 
grown in vitro. Alpha- a nd ,8-adrenergic receptor subtype clas-
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sification is based on the relative potency order of stimulation 
of adenylate cyclase activi ty as reviewed by Lefkowitz and 
Hoffman [15], and we h ave employed natural catecholamines 
and several new antagonists which can selectively bind to 
adrenergic receptors. 
MATERIALS AND METHODS 
Epidermal Cell Cultures 
P rimary human keratinocytes were prepared as previously described 
(16] from meloplasty specimens obtained from women, aged 50- 61 
yea rs (mean= 56 years). Briefly, 0.1-mm keratotomed slices of epider-
mis were incubated in 0.3% trypsin and 0.1% EDTA in 150 mM NaCl, 
0.04% KCl, 0.1% glucose, pH 7.3, for 30 min at 37°C. The cells were 
suspended in complete growth medium which consisted of Dulbecco 's 
min imum essential medium plus 10% heat- inactivated fetal ca lf serum, 
2 mM L-glu tamine, 50 l'g/ml gentamicin, 50 l'g/ml streptomycin, and 
50 units/ml penicillin . Cells were plated at a density of 2 X 10" viable 
cells on Petri dishes coated with collagen (16] and main ta ined at 37°C 
in 5% CO" humidified conditions. Medium was changed twice a week. 
Adenylate Cyclase Assay 
The activity of adenyla te cyclase was studied by the formation and 
accumulation of ["H)-cAMP form ed from ["H]-ATP in ce lls prelabe led 
with ["H)-adenine in a procedure adapted for epidermal cell cultures as 
descri bed by Wilkinson and Orenberg [17]. At days between 3-5 after 
pla ting, when keratinocytes are in a prolife rative phase, dishes of ce lls 
were se lected in triplicate, media aspirated, and ["H)-adenine (5 I'Ci in 
2.0 ml serum-free growth medium) added to each dish for 2 h at 37°C. 
Then the medium was aspirated, the cells were cha llenged with an 
adrenergic agonistic agent for 15 min at 37°C in phosphate-buffered 
saline (PBS) (2 ml) conta ining the phosphodiesterase inhibi tor, isobu-
tylmethylxanthine (IBMX, 1.0 mM). The test drugs included one of the 
following: L-isoproterenol (ISP) , L-epinepluine (EPI) , or L-norepi-
nephrine (NE) at 1.0- 10 to 10- " M; phenylephrine (10- ' to 10_,, M) ; or 
clonidine ( 10-" to w-'• M) . In some experiments, ce lls were treated with 
an adrenergic antagonistic drug for 10 min at 37°C between the ["H)-
adenine prelabeling and cha llenge with an agonist; included were either 
one of the /3-antagonist drugs, atenolol, L-propranolol (PRP), or butox-
amine at 10- 7 to 10- :J M; or one of the a-an tagonist drugs, prazosin, 
phento lamine, or yohimbine at 10- 7 to 10-" M. Control dishes received 
only PBS with IBMX. After drug exposure, t he medium was poured 
off, each dish quickly rinsed with PBS at 37°C, and then ice-cold 5% 
trichloroacetic acid (2 ml) was added. The ["H)-cAMP formed was 
sepa rated and purified using sequentia l chromatography on columns of 
Dowex exchange resin a nd aluminum oxide as described by Salomon et 
al [18]. The procedures for determination of adenylate cyclase activity 
were va lidated with consideration of t he following: that a time depend-
ent and linear formation of [aH]-ATP from ["H)-adenine occurs in the 
2-h prelabel period; t hat ["H)-cAM P formation reaches a maximum 
after 15 min in the presence of an adrenergic agonistic drug and IBMX; 
and that ['H)-adenine labels t he ATP pool in a representative manner. 
The latter was proved by incubation of cells for 2 h in para llel experi-
ments with t he quantity of cold adenine equivalent to 5 I'Ci of ["H)-
adenine, followed by cha llenge with various agonists, and assay of 
cAMP formed by radioimmunoassay (RIA). Comparison of prelabeling 
and R IA methods indicated t hat the relative formation of ["H)-cAMP 
and cAMP was very s imilar [17]. Examination of "H distribution among 
intracellular adenine nucleotides after prelabeling, using PEl -cellulose 
chromatography for separation of these compounds, showed that over 
80% of t he label was consistent ly associated with ATP [17] a nd this 
pattern was maintained in those cases where a 10-min incubation with 
antagonists was performed. 
Materials 
Tissue cul ture supplie? were obtained from Microbiological Associ-
ates and Grand Island Biological Company, Lux Petri dishes from Flow 
Laboratories, and [2-"H]-adenine (sp.act. 15 Ci/mmol) from New Eng-
land Nuclem. L-isoproterenol, L-epinephrine, L-arterenol (norepineph-
rine), phenylephrine, and yohimbine chloride were obta ined from 
Sigma Chemical Co. (St. Louis, Missouri), atenolol from Stua rt P har-
maceuticals (Wilmington, Delaware), clonidine HCI from Boehringer-
l ngelheim (Ridgefield, Connecticut) , and prazos in from P fizer Labora-
tories (New York, New York) . The following compounds were received 
as generous gifts: L-propranolol from Ayerst Laboratories (New York, 
New York); butoxamine HCI from Burroughs-Wellcome (Triangle 
Park , North Carolina); and phento lamine HCI (R~gi tin e H CI) from 
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Ciba-Geigy Corp. (Summit, New Jersey). All other chemicals were 
reagent grade. 
RESULTS 
Since many tissues contain both a - and ,8-receptors, the first 
consideration was to categorize those responses to the synthetic 
and natura! catechola mines which are attributed to the two 
major receptor classes. A summary of naturally occurring ad-
renergic agonists as well as drugs that can selectively stimulate 
or block cv- and ,8-adrenergic receptors is presented in T able I. 
These agonists were used to determine the relative potency 
orders for characterizatio n of adTenergic receptor subtypes pre-
sent on human epidermal keratinocytes. The ,8-adrenergic re-
ceptors are stimulated by catecholamines with the rank order 
of potency ISO > EPI » NE for ,82-receptors and ISO > EPI 
= NE for ,B,-receptors. For a -adrenergic receptors the order is 
NE > EP » ISO [19]. 
Challenge of keratinocytes with ISP, EPI, and NE resulted 
in a dose-dependent increase in formation of eHJ-cAMP (Fig 
1). Cells were responsive to dl·ug concentrations as low as 10- 10 
M . In terms of relative potency, the response to ISP was 3-fold 
greater ( p < 0.001) than that elicited by EPI, and 14-fold 
greater than NE at this concentration . The maximum nucleo-
t ide conversion occurred with ISP and EPI at 10- 7 M, and at 
10- !i to 10_,, M with NE. For receptor-mediated responses that 
are characteristic ofthe ,8-adrenergic receptor the potency order 
is ISP > EPI which is in turn either equipotent or greater than 
NE. This is in keeping with the potency order observed. First-
passage keratinocytes prepared from the primary cultures as 
described [16] had similar responses to catecholamine stimu-
la tion (data not shown). 
Since NE is a potent amine associated wi th (¥-adrenergic-
mediated responses, experiments were conducted to confirm 
that the cAMP formation resulting from NE stimulation was 
predominantly a ,8-adrenergic receptor-mediated effect which 
could be elici ted at high NE concentrations. The results ob-
tained by incubation of human keratinocytes with a - and ,a-
antagonists prior to NE (lo- u M) exposure are shown in T able 
II. Phentolamine which is specific for a-adrenergic receptors 
had no inhibitory effect on the stimulation of adenylate cyclase 
activi ty by NE, nor did yohimbine. Prazosin was effective only 
at 10- a M . Addition of PRP (10- 7 M) resulted in complete 
inhibi tion of adenylate cyclase activity. In contrast, atenolol, 
the ,B, -selective antagonist, produced 37% inhibition of enzyme 
activity but required a concentration 200-fold higher. Therefore, 
the potency order for the adrenergic antagonists was PRP > 
atenolol » prazosin. Thus only the ,8-antagonists had an ap-
preciable inhibitory effect on NE stimulation. 
When phenylephrine, the a,-specific agonist was run in a 
potency series test the response in terms of formation of [3H]-
cAMP was similar to that produced by NE. Adenylate cyclase 
activity was increased by phenylephrine (10- 7 to 10- " M) in 
curves that were parallel and not significantly differ ent from 
NE (data not shown). The formation of ["H)-cAMP by phen-
ylephrine, which for example yielded 8.78% conversion of 
["H]-ATP to [3H)-cAMP at 10_,, M, was reduced approximately 
60% after preincubation wi th the a,-specific antagonist prazosin 
(Ta ble III) . Another cellular mecha nism other than a direct 
receptor-mediated response-perhaps stimulation of the cal-
TABLE I. Natural and synthetic catecholamines and drugs that 
affect a- or {3 -adren.ergic receptors 
Agonists An tagonists 
f3 , Norepinephrine Atenolol* 
[1,, !3~ Isoproterenol P ropranolol 
/3z Epinephrine Butoxamine* 
a , Phenylephrine* Prazos in* 
0 ']' 0'2 NE = EPI Phento lamine 
(\'2 Clonidine* Yohimbine* 
* Drugs selective for adTenergic receptor subtype. 
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FIG 1. The effects of the ,G-adrenergic agonists, IS P, EPl, a nd NE, 
in t h e formation of ["H)-cAMP from [3H]-A TP in huma n keratinocytes 
prelabeled wit h ["H)-adenine. Proliferating cells (days 3-5 after plat ing) 
wer e incubated with t he catecholamines for 15 min in the presence of 
IBMX (1 x 10-" M) . R esul ts are expressed as mea n ± SEM of t riplicate 
dishes tested simul taneously. 
TABLE II. Effects of a· and ,8-selective antagonists on the ability of 
NE (10- u M) to stimulate adenylate cyclase activit.y 
Antago nis t 
Prazosin 
( a ,) 
P hentolamine 
(a, a nd a" ) 
Yohimbine 
(a" ) 
Atenolol 
(,G,) 
Propranolol 
(,B, a nd ,B") 
10- 7 M 
10- r, M 
10- a M 
10- r. M 
10- •l M 
10- 7 M 
10- '' M 
10- 7 M 
10- r, M 
10-a M 
10- 7 M 
10- 5 M 
10- " M 
10- a M 
Per cent inhibi tio n of anenylate cy· 
clase activity 
None 
0.6 
84 
None 
None 
None 
None 
None 
37 
88 
100 
100 
100 
N one 
TABLE III. Effects of the a-adrenergic agonists, pheny lephrine and 
clonidine, and the a 1-antagonist, prazosin, on formation of [lH]· 
cAMP from. [3Hj-A TP 
Drug 
Phen ylephrine (PHE) 
Prazosin· 10- 7 M + PHE 
10- ,; M + PHE 
10_,, M + PHE 
Clonidine 
10-" M 
10- 7 M 
10- r, M 
10- '' M 
10- '• M 
10- '• M 
10-" M 
10- r. M 
PercenL conversion of ["HJ-ATP 
to ["H)-cAMP 
0.08 
0.20 
8.78 
2.97 
3.35 
3.60 
0.06 
0.04 
cium channel-may account for t he effect seen with phenyleph-
rine. Clonidine, the 0'2-adrenergic drug that is known to inhibi t 
adenylate cyclase activi ty in other cell systems, had no affect 
on the human keratinocytes. 
To further characterize the ,8-adrenergic receptor subtypes 
present on the keratinocytes, ,8-subtype selective antagonists 
were used to evaluate the potency order of inhibition of ade-
nylate cyclase activi ty after EPI and ISP stimulation. A graph 
representative of 4 replicate experiments on prolifera t ing kera-
t inocytes i given in Fig 2. PRP with ,B,- and ,82-receptor 
· blocking proper t ies reduced the response to EPI (10- u M) by 
95% at 10- 5 M, whereas butoxamine, the ,82-selective antago nist 
inhibited the EPI response by 20% at 10- '· M, and by 68% at. 
10- :l M . Atenolol (,8,-selective antagonist) had no significant 
effect. ISP (lo- •; M) was also tested in the same manner. The 
inhibition of adenylate cyclase activi ty with PRP and butox-
amine was simila r to that shown with EPI. At 10- 5 M, PRP was 
effective in blocking 90% of the enzyme activity, butoxamine 
25%, and atenolol 15%. This relative potency order for the 
antagonist suggests that the majority of ,B-ad1·energic receptors 
are of t he ,82-subtype. 
100 
80 
60 
40 
>. 20 
-> 
-0 
0 
CD 
Ill 
0 
~ 100 
0 
CD 
-0 
>. 80 
c 
~ 
0 
.... 
0 
c 
0 
-:a 
.J:. 
c 
60 
20 
Epinephrine (lo· 6 MJ 
Butoxamme 
Isoproterenol (IQ-6MJ 
Butoxamine 
(32 
Propranolol 
Prcpronolol 
~~. /32 
Drug concentration (M) 
Atenolol 
Atenolol 
/31 
FIG 2. The effects of selective ,a-adrenergic antagonistic drugs on 
the inhibi t ion of EPI- a nd ISP-stimulated formation of [''H)-cAMP 
from [aH]-ATP as an index of adenylate cyclase activity. K eratinocytes 
were incubated wit h eit her butoxamine, PRP, or atenolol at the indi-
cated concentrations, then cha llenged with either EPI or ISP (lo- •; M) 
in t he presence of IBMX (1 X lO- " M). A typical % conversion ["H]-
ATP to [aH]-cAMP was 4.06-4.43% wi th EPI or ISP (lo- •; M). Resul ts 
a re reported as % inhibi tion of a denylate cyclase activity. 
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Rank potency orders of ISP, EPI, and NE stimulation also 
were evaluated in the epidermal keratinocytes as cells matured 
in culture. Cul tures were selected for testing at a n early point 
in culture, such as day 5, which consists primarily of a prol if-
erating population, and at days 15, 23, and 30 when cul tur es 
were multilayered with many differentiating cells. At each day 
the potency order of stimulation of adenylate cyclase activity 
was similar with ISP > EPI » NE, but the magnitude of 
response (% conversion of [lH]-ATP to ["H)-cAMP) was slightly 
increased in older cultures (data not shown) . 
DISCUSSION 
These studies demonstrate that the adenylate cyclase-cou-
pled /3-adTenergic receptor popu latio n of human epidermal 
keratinocytes is predominantly a /32-receptor. However, the 
major physiologic distinction between the /3- receptor subtypes 
(/3 1 and /32) is the differential sensitivi ty toNE. The responses 
to EPI were a magni tude greater than the NE, as is character-
istic of /3~-receptors. Further confirmation of this classification 
is achieved with selective antagon ists [19,20]. PRP and bu tox-
amine effective ly blocked ISP and EPI, whereas ate nolol with 
f3,-se lectivity had li t tle to no effect in inhibi t ing the response 
elicited with these ago nists. 
However, we cannot completely rule out the possibili ty that 
both /3-adTenergic receptor subtypes may coexist in epidermis. 
Whil e our keratinocyte cultures conta in cells primarily derived 
from the basal a nd malpighian layers, other cells including 
melanocytes, Merkel cells, and Langerhans cells may be pre-
sent, a lthough in relatively few numbers. There is evidence for 
existence of f3,- a nd /32-receptors in brain and cardiac tissue, 
each governing separate fun ctional properties. The presence of 
both types may simply reflect heterogeneity of cell types within 
an organ. 
It has been suggested that in general f3,-receptors be consid-
ered as neuronal receptors a nd /32-receptors as hormonal recep-
tors [21]. Some doubt still exists with regard to the receptor-
mediated responses eHcited with NE in the huma n keratino-
cytes in t_his study. This endogenous catecholamine is a f3,-
selective ago nist. At high but physio logic concentrations (10- " 
to w-r. M) NE stimulates cAMP formation. That th is effect is 
completely inhibi ted by PRP, a drug with f3,a nd /3~-selectivi ty, 
and in potency order, secondarily, by atenolol wi t h f3, -selectivity 
may suggest the presence of /3 1-receptors. Radioligand binding 
assays are now being employed to clarify this issue by distin-
guishing between and quantifying the /3-adrenergic receptor 
subtype(s) in epidermis. 
The catecholamines and drugs used for the receptor classifi-
cation studies were those that have been reported to show good 
agreement of selectivity in physiologic experiments with intact 
t issue, in radioligand binding assays, and in biochemical studies 
of adenylate cyclase activity in vitro [19,20]. The preliminary 
studies examined the relative potencies of the EPI and NE. EPI 
is a natural agonist for /32-receptors and kn own to induce cAMP 
formation in epidermis [22]. The endogenous catecholamines 
were used in preference to drugs such as salbutomol wh ich is a 
/32-receptor ago nist for adenylate cyclase. However, this agent 
has similar affinity for bot h /3-subtypes in binding assays a nd 
can be an an tagonist of /3 1-receptors [23]. 
We have no evidence for t he presence of a-adJ·energic recep-
tors in the cultured . human keratinocytes. In cells such as 
platelets and adipocytes, az- receptors a re coupled in an inhi bi-
tory fashion to adenylate cyclase such that stimulation of the 
receptor results in decreased intracellula r cAMP levels. We 
used clonidine, the specific a 2-adrenergic agent, and produced 
no a lte rations in adenylate cyclase activity. In all cell systems 
so fa1· studied there is, however, no indication that a ,-adrenergic 
receptors are coupled to adenylate cyclase. In the human ker-
atinocytes exposed to high concent rations (lo- r, M) of p henyl-
ephrine, the observed increase in adenylate cyclase activity 
Vol. 80, No. 6 
may resul t from a nonspecific drug effect associated with alter-
ations in the calcium channel which in turn increases cAMP. 
Prazosin, the specific a,-antagonist only pa1·tially reduced the 
effect of phenylephrine. In outgrowth cul tures of human epi-
dermis [24] the catecholamines (ISP, NE, a nd EPI) as well as 
phenylephrine produced mitotic inhibi t ion. Since this response 
could be blocked by PRP and not by phentola mine, it was 
suggested the phenylephrine may have /3-receptor stimulating 
properties [25]. The endogenous catechol amine NE acts as a 
f3, -selective agonist but a lso may stimulate a -adrenergic recep-
tors. Our finding that the NE-stimulated increase in cAMP is 
totally blocked with PRP indicates NE acts t hrough /3- recep-
tors. The lack of inhibition with phentolamine fwther substan-
tiates t he absence of /3-adTenergic recepto rs. In contrast to om 
study with human epidermis, in mouse epidermal sheets t he 
inhibition of metabolic rate attribu ted to NE could not be 
reduced by PRP bu t was inhibi ted wi t h phentolamine [11]. 
These authors therefore suggest that this is an a -receptor-
mediated response. This difference may be attributed to species 
differences in adrenergic responses between huma n a nd rodent 
cells or may be a consequence of cell heterogeneity in the 
epithelial samples studied. 
Association of cAMP with marked increased proliferation 
rate and red uced epidermal cell differentiation in the psoriatic 
disease process is forwarded by numerous clinical observations 
that drugs which exacerbate pso riasis may possibly do so by 
preventing cAMP accumulation. Flaring of psoriasis has been 
noted in patients treated with iodine, ant imalarials, bthium 
carbonate for depression [26], a nd the /3-adrenergic blocking 
agents, practolol and PRP, for hyper tens ion and cardiovascular 
disease [27,28]. Lithium salts decrease the responsiveness of 
adenylate cyclase to stimulation at 3 independent receptor sites 
[29]. The /3-receptor antagonist, PRP, selectively stimulates 
DNA synthesis in involved psoriatic skin after intradermal 
injections as compared with normal skin [30] and also may 
produce psoriasiform rashes in experimental animals [31]. 
These data indicate that the /3-adrenergic receptors may have 
fun ctiona l significance in the regulation of epidermal growth. 
Classification of adrenergic receptors in human epidermal 
ke ratinocytes represents bu t a first step in evaluating the phys-
iologic function of these receptors. While alterations in aru·e-
nergic receptors have been ident ified in numerous diseases 
[32], pathophysiology involving these receptors is now only 
speculative with regru·d to skin. Differences in epidermal re-
sponsivene s to catecholamines a nd possible variations in intra-
cellular concentrations of cAMP implicate adrenergic receptors. 
Knowledge of the putative role of /3-adrenergic receptors will 
be advanced by raclioligand binding studies to determine num-
bers of receptors and receptor affinity for agonists, as well as 
pharmacologic agents that may modulate receptor function. 
Use of in vitro model systems with relatively homogeneous cell 
populations will greatly benefit these endeavors . 
The authors graLefully acknowledge the technical assistance of Miss 
Angelica Griffin . 
REFERENCES 
l. Powell JA, Duell EA, Voorhees JJ: Beta ad renergic stimulation of 
endogenous epiderma l cyclic AMP fo rmation. Arch Dennatol 
104:359-365, 1971 
2.· liwka H, Adachi H , Halprin KM, Levine V: Histamine (H2) recep-
tor-adenylate cyclase system in pig sl<in(epidermis). B iochim 
Biophys Acta 437:1 50- 157, 1976 
3. Adachi K, lizuka H, Halprin KM , Levine V: S pecific refracto riness 
of adenylat.e cyclase to epinephrine, prostaglandin E, histamine 
a nd AMP. Bioch im B iophys Acta 497:428-436, 1977 
4. Duell EA: Adenosine-induced a lterations in Lhe adenos ine 3':5'-
monophosphate levels in mammalia n epidermis. Mol Phannacol 
18:49-52, 1980 
5. Adachi K, Yoshikawa K, Ha lprin KM, Levine M: P rostagla ndins 
a nd cyclic AMP in epidermis. Br J Dermato l 92:381-388 1975 
6. Wilkinson Dl, Orenberg EK: Change with maturat ion in' the re· 
June 1983 
spon e of keratinocyte adenylate cyclase to agonist (abstr). Clin 
Res 26:1 56, 1981 
7. Yoshikawa K, Adachi K, Halprin KM , Levine V: On the lack of 
r esponse of catecholamine stimulation by the adenyl cyclase 
system in p oriatic lesions. Br J Dermatol 92:619-624 , 1975 
8. Aso K , Orenberg EK, Farber EM: Reduced epidermal cyclic AMP 
accumulation fo llowing prostaglandin stimulation: its possible 
role in the pathophysiology of psoriasis. ,} Invesl Dermatol 
65:375-378, 1975 
9. Iizuka H , Umeda K, Koizumi H , Aoyagi T , Miura Y: Epinephrine-
induced cycl ic AMP accumulation in the psoriatic epidermis. 
Acta Derm Venereal (Stockh) 61:391-395, 1981 
10. Mahrle G, Orfanos CE: Ultrastructural localization and di ffe rentia-
t ion of membrane-bound ATP utilizing enzymes including adenyl 
cyclase in norma l and psoriatic tissue. Br J Dermatol 93:495-507, 
1975 
11. Harris RR, Mackenzie IC: T he effects of a and fJ adrenergic agonist.s 
and cyclic adenosine 3':5'-monopho. phate on epidermal metab-
olism. J Invest Dermatol 77:337-340, 1981 
12. Solanki V, Murray A W: The {J-adr energic receptor of newborn 
mouse skin. J Invest Dermatol 71:344-346, 1978 
13. Duell E: Identification of a beta"-adrenergic recepto r in mammalian 
epidermis. Biochem Pharmacol 29:97-101, 1980 
14. Gazith J , Reichert U: H igh affini ty membrane receptors in cul tured 
keratinocytes. T. The {J-adrenergic receptors. B r J Dermatol 107 
(suppl 23):1 25-133, 1982 
15. Lefkowitz HJ, Hoffman BB: Adrenergic receptors, Advances in 
Cyclic Nucleotide Research. Edited by P Hamet, H Sands. New 
York, Raven Press, 1980, vol 12, pp 37-47 
16. Liu S-CC, Karasek M: Isolation and growth of adul t human epi-
dermal keratinocytes in cell cul ture. J Invest Derma to! 71:157-
162, 1978 
17. Wilkinson Dl, Orenberg El<: Retinoids increase the sensitivity of 
guinea pig but not human kerat inocytes to agonist;s of adenylate 
cyclase in. vitro . Arch Dermatol Res, in press, 1983 
18. Salomon Y, Londos C, Rodbe ll M: A highly sensitive adenylate 
cydase assay. Anal B iochem 58:541-547, 1974 
19. Minneman KP, Pittman RN , Molinoff PB: ,8-adrenergic receptor 
s ubtypes: properties, distribu tion, and regulation. Ann Rev Neu-
0022-202X/83/800!i-0507$02.00/ 0 
THE JOURNAL OF I N VESTI GATI VE DEHMATOLOGY, 80:507-5 14 , 1fJ8;J 
Copyrigh t© 198;3 by The Willi ams & Wilkins Co. 
PENETRATION ENHANCERS FOR HUMAN SKIN 507 
rosci 4:419-461, 1981 
20. Leclerc G, Rouot B, Velly J, Schwartz: {J-adrenergic receptor sub-
types, Towru-ds Understanding Receptors. Edited by JW Lambe. 
Amsterdam, E lsevier/ North-Holland, 1.981, pp 78-83 
21. Carlsson E, Hedberg A: Are cardiac effects of catecholamines 
noradrenaline and adrenaline mediated by different ,B-adrenocep-
tors? Acta Physiol Scand [S uppl] 44:47, 1977 
22. Iizuka H, Umeda K, Koizumi H, Aoyagi T , Miura Y: Epinephrine-
induced cycl ic AMP accumulation in psoria tic epidermis. Acta 
Derm Venereol (Stockh) 61:391-395, 1981 
23. Minneman KP, Hegstrand LR, Molinoff PB: The pharmacologica l 
specificity of beta-1 and beta-2-adrenergic receptors in rat heart 
and lung in vitro. Mol Phannacol 16:21-33, 1979 
24. Harper RA, Flaxman BA: Effect of Pharmacological agents in 
human keratinocytes mitos is in vitro. J Cell Physiol 86:293-299, 
1975 
25. Wagner J , Endoh M, Reinhardt D. Stimulation by phenylephrine 
of adrenergic a lpha and beta-receptors in the isolated perfused 
rabbit heart. Naunyn Schmiedebergs Arch Phannacol 282:307-
310, 1974 
26. Mobacken H, Magnusson BL: Lette1·: Different pathogenesis for 
psoriatic reaction to li thium and practolol? BrJ Dermatol98:597-
598, 1978 
27. Brigden WD, Almeyda J : Adverse reaction to ,B-adrenergic blocking 
drugs. Br J Derma to! 95:335-338, 1976 
28. Cochran REI, Thomson J , McQueen A, Beevers DG: Skin reactions 
associated with propranolol. Arch Dermato l ll2:ll73-1174, 1976 
29. DiGiovanna JJ , Aoyagi T , Taylor JR, Halprin KM: Inhibition of 
epidermal adenyl cyclase by li t hium carbonate. J Invest Derma-
to! 76:259-263, 1981 
30. Wiley HE, Weinstein GD. Abnormal proliferation of uninvolved 
psoriatic epidermis: differential induction by saline, propranolol, 
and tape stripping in vivo. J Invest Dermatol 73:545-54 7, 1979 
31. Gaylarde PM, Brock AP, Sarkany I. Psoriasiform changes in 
guinea-pig skin from propranolol. Clin Exp Dermatol 3:157-160, 
1978 
32. Motulsky HJ , Insel PA. Adrenergic recepto rs in man: direct iden-
t ification, physiologic regu lation, and clinical a lterations. N Eng! 
J Med 307:18-29, 1982 
Vol. 80, No. (i 
Printed in U.S.A. 
Penetration Enhancers for Human Skin: Mode of Action of 2-Pyrrolidone 
and Dimethylformamide on Partition and Diffusion of Model Compounds 
Water, n-Alcohols, and Caffeine* 
DIANE SouTHWELL, PH.D. AND BRI AN W. BARRY, PH.D., D.Sc. 
Postgraduate School of S tudies in Pharmacy, University of Bradford, Bradford. West York,h ire, U.K. 
Penetration-enh a ncing solvents may modify diffu-
sional routes through the stratum c orneum and the par-
titioning of drugs into these p athways. To investigate 
the mechanisms of action of enhancers, steady-state 
fluxes were measured in vitro for polar methanol, non-
polar octanol, and an interm ediate compound, caffeine, 
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33(suppi]:1P, 1981. 
Reprint requests to: Dr. B rian W. Barry, P ostgraduate School of 
Studies in Pharmacy, University of Bradford, Bradford, West Yorkshire 
BD7 lDP, E ngland. 
Abb reviations: 
DMF: dimethylformamide 
DMSO: dimethylsulfoxide 
2-P: 2-pyrro lidone 
s .c.: stratum corneum 
selected as model penetrants; human stratum corneum 
conditioned on both sides with water or accelerants (2-
pyrrolidone or dimethylformamide solutions) was u sed. 
We determined partition, permeability, and apparent 
diffusion coefficients, and derived t h e s tandard free en-
ergy of transfer of the m ethyle n e group from water to 
stratum corneum ( - 423 cal mol - '); less n e gative values 
w e re obtained for transfer from 2-pyrrolidone solutions. 
We conclude that for these model compounds, and taking 
a fully h ydrated membrane as a standard: (a) 2 -pyrroli-
done e nhances p ermeation throu gh the polar route of 
the skin by increasing the diffus ivi ty, and r e duces pas-
sage through the nonpolar route by decreasing diffusiv-
ity and partitioning, (b) dimethylformamide promotes 
polar route absorption by raising diffusivity and parti-
tioning and reduces nonpolar absorption b y decreasing 
both parameters, and (c) for caffeine, the markedly in-
creased absorption (15-fold) caused by dimethylformam-
ide i s associated with damage to the membrane. 
